HALEOS LABS LIMITED (HALEOSLABS) — encumbrance | 12 June 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Haleos Labs Limited disclosed that its promoters and promoter group have not encumbered any shares during the financial year ending March 31, 2026, as required under SEBI takeover regulations. The filing confirms no new encumbrances were created, maintaining the existing shareholding structure without additional pledges or restrictions. This transparency reinforces investor confidence in the stability of the company's ownership profile ahead of the upcoming annual meeting.

📄 View Original Announcement (PDF)

About HALEOS LABS LIMITED (HALEOSLABS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹460.98 Cr P/E: 29.2 ROE: 7.8% ROCE: 10.0% Div Yield: 0.10%

View full HALEOSLABS stock details →

📡 Get AI alerts when HALEOSLABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track HALEOSLABS — Free

📊 More HALEOSLABS filings

See all HALEOSLABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HALEOSLABS files new disclosures

Track HALEOSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HALEOSLABS — Free

Free account · 2 AI queries/day